Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
>objective: Cognitive dysfunction is a common symptom of post-COVID-19 condition (PCC). Few studies have examined rates and predictors of cognitive performance validity test (PVT) failure in patients seeking treatment for PCC.
>methods: We report the rates of PVT failure in 323 patients who received care in a long-COVID-19 clinic for any post-COVID-19 health concern and underwent routine telephone cognitive testing that included two embedded PVTs. Binary logistic regressions examined the demographic, illness, and psychological variables associated with PVT failure.
>results: The prevalence of single PVT failure ranged from 4.7% to 26.1% whereas failure on both PVTs occurred in just 6.3%. Illness characteristics, subjective cognitive dysfunction, and most demographic and psychological variables were unrelated to single PVT failure. Males and those with anxiety were more likely to fail both PVTs.
>conclusion: Failure across multiple PVTs was not common and was unrelated to COVID-19 severity or cognitive complaints.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290880 | PMC |
| http://dx.doi.org/10.1093/arclin/acae122 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Cardiovascular Outcomes With Bisoprolol: An Evidence-Based Perspective.
Cureus
August 2025
Department of Cardiology, Apollo Hospitals, Indore, IND.
The cardiovascular continuum is the developmental process of cardiovascular diseases (CVDs) leading to heart failure (HF) and sudden cardiac death. Beta-blockers (BBs) are at the forefront of managing conditions along this continuum, ranging from cardiovascular (CV) risk factors to heart failure. In particular, bisoprolol proved to be a highly cardio-selective BB with a favourable pharmacokinetic profile, demonstrating long-term safety, good tolerability, and proven efficacy in reducing cardiac events, including arrhythmias and mortality in patients with heart failure with reduced ejection fraction (HFrEF).
View Article and Find Full Text PDFBRIDGE-DS study: evaluating the effectiveness and safety of dapagliflozin/sitagliptin combination in type 2 diabetes mellitus patients with heart failure.
Cardiovasc Endocrinol Metab
December 2025
Department of Endocrinology, Scientific Services, USV Pvt. Ltd, Mumbai, Maharashtra, India.
Background: Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function.
Aim: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.
J Am Coll Cardiol
September 2025
Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
Background: Genetic variants in cardiomyopathy genes are associated with risk of atrial fibrillation (AF), although data on clinical outcomes for AF patients with such variants remain sparse.
Objectives: We aimed to study the prognostic implication of rare cardiomyopathy-associated pathogenic variants (CMP-PLP) in AF patients from large, well-phenotyped clinical trials.
Methods: CMP-PLP carriers were identified using exome sequencing in 5 multinational trials from the Thrombolysis in Myocardial Infarction study group (ENGAGE AF, FOURIER, SAVOR, PEGASUS, and DECLARE), with replication in the EAST-AFNET-4 trial.
Nonsteroidal and Steroidal Mineralocorticoid Antagonists: Rationale, Evidence, and Unanswered Questions.
JACC Heart Fail
August 2025
Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri, USA. Electronic address:
Steroidal mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, have demonstrated substantial benefits in randomized controlled trials for patients with heart failure with reduced ejection fraction. However, their effectiveness in heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction remains uncertain, and the implementation of this class has remained low, in part due to its side effects and tolerability profile. Emerging therapies that target the mineralocorticoid receptor and/or the production of aldosterone may offer alternative strategies to treat the aldosterone-mineralocorticoid receptor axis.
View Article and Find Full Text PDFExtracorporeal therapies for post-liver transplant recipient: The road less traveled.
World J Transplant
September 2025
Institute of Critical Care and Anesthesiology, Medanta-The Medicity, Gurugram 122001, Haryana, India.
Extracorporeal therapies have a definite role in patients with acute liver failure, acute on-chronic liver failure, and progressive chronic liver disease. They act as a bridge-to-transplant in these patients. With the increasing success of liver transplantation, the immediate postoperative complication spectrum continues to expand.
View Article and Find Full Text PDF